Table 4.
Criteria | Comment regarding CKD screening | |
---|---|---|
1 | The screening programme should respond to a recognized need. | The current situation of population ageing with increasing incidence of CKD and ESRD and their associated costs strongly suggest that there is a need. |
2 | The objectives of screening should be defined at the outset. | The objective should be to decrease all-cause and CV mortality as well as ESRD incidence and mortality and also to improve the quality of life of people living with CKD. |
3 | There should be a defined target population. | Although no consensus exists for CKD screening, the sharp age-related increase in CKD prevalence suggests starting screening after the age of 50 years. |
4 | There should be scientific evidence of screening programme effectiveness. | No such evidence currently exists. |
5 | The programme should integrate education, testing, clinical services and programme management. | No programme is currently being tested. |
6 | There should be quality assurance, with mechanisms to minimize potential risks of screening. | No programme is currently being tested. |
7 | The programme should ensure informed choice, confidentiality and respect for autonomy. | No programme is currently being tested. |
8 | The programme should promote equity and access to screening for the entire target population. | No programme is currently being tested. |
9 | Programme evaluation should be planned from the outset. | No programme is currently being tested. |
10 | The overall benefits of screening should outweigh the harm. | No such evidence currently exists. |
CKD chronic kidney disease, CVD cardiovascular disease, ESRD end-stage renal disease